Cognitive Biomarkers in Pediatric Brain Tumor Patients

Get Involved

Cognitive Biomarkers in Pediatric Brain Tumor Patients

Study Purpose

The investigators will focus on three cohorts of brain tumor patients aged, 4-18 years, to answer two critical questions: 1) Can the investigators acquire high quality data relevant to cognitive function during the peri-diagnostic period and, 2) can the investigators develop predictive models for cognitive outcomes using serial examination of functional imaging and cognitive function. Any patient with a newly diagnosed brain tumor aged 4-18 will be eligible for enrollment in cohort 1. Only patients with previously diagnosed tumors of the posterior fossa will be eligible for cohort 2. For cohort 3, eligible patients will include patients with a clinical diagnosis of posterior fossa syndrome with physical impairments that prohibit completion of the NIH Toolbox Cognitive Battery. The investigators have decided to expand the eligible tumor types to better capture the most significant deficit variability that can be caused by tumors outside the posterior fossa. Thus, this focus will provide a platform to analyze the impact that different tumor types and different standard treatments have on cognitive dysfunction. The rationale for inclusion of subjects on cohort 3 is that posterior fossa syndrome is one of the most cognitively devastating diagnoses following a posterior fossa surgery. The causes of posterior fossa syndrome and unknown and there are currently no interventions to improve symptoms. RsfcMRI would offer a novel and non-invasive assessment of posterior fossa syndrome patients by assessing connectivity within and outside of the cerebellum. Expanding the tumor eligibility will allow us to further explore the effect tumor location will have on cognitive testing and rsfcMRI. Here, repeated evaluations on and off therapy will provide the necessary data points to establish trajectories of cognitive development and recovery in this population.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	4 Years - 18 Years
Gender	All

More Inclusion & Exclusion Criteria

Cohort 1 (30 patients will be enrolled to this cohort)

Inclusion Criteria:

- Between 4 and 18 years of age, inclusive.

- Newly diagnosed primary brain tumor of any location and any histology.

- Life expectancy of at least one year.

- Able to understand and willing to consent or assent to the research proposed, along with consent of legal guardian(s) if applicable.

Exclusion Criteria:

- Presence of visual impairment to an extent that the patient is unable to complete the computer testing.

- Contraindication to MRI scan (i.e. due to cardiac pacemaker) - Programmable Shunt.

Cohort 2 (150 patients will enrolled to this cohort. This may include some or all of the patients enrolled to Cohort 1.)

Inclusion Criteria:

- Between 4 and 18 years of age, inclusive.

- Previous diagnosis of a posterior fossa brain tumor; patients who are either undergoing active treatment for posterior fossa tumor or who have completed treatment will be eligible for study enrollment.

- Life expectancy of at least one year.

- Able to understand and willing to consent assent to the research proposed, along with consent of legal guardian(s) if applicable.

Exclusion Criteria:

- Presence of visual impairment to an extent that the patient is unable to complete the computer testing.

- Contraindication to MRI scan (i.e. due to cardiac pacemaker) Cohort 3 (20 patients will be enrolled to this cohort.

This may include some or all of the patients enrolled to Cohort 1) Inclusion Criteria.

- Between 4 and 18 years of age, inclusive.

- Previous diagnosis of a posterior fossa brain tumor.

- Clinical diagnosis of post-operative posterior fossa syndrome.

- Inability to complete NIH Toolbox.

- Life expectancy of at least one year.

- Able to understand and willing to consent assent to the research proposed, along with consent of legal guardian(s) if applicable.

Exclusion Criteria.

- Contraindication to MRI scan (i.e. due to cardiac pacemaker) Cohort 4 (50 Patients will be enrolled to Cohort 4.

This will include patients previously enrolled on Cohorts 1-3 above.) Inclusion Criteria.

- Between 12-30 years of age, inclusive.

- Diagnosis of a brain tumor >3 years prior to study enrollment.

- Life expectancy of at least one year.

- Able to understand and willing to consent assent to the research proposed, along with consent of legal guardian(s) if applicable.

- Patient must be able to complete a 1 hour MRI scan without sedation.

Exclusion Criteria.

- Contraindiciation to MRI scan (i.e. due to cardian pacemaker) - Presence of dental braces or programmable shunt.

- Patient requires sedation for MRI scan

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT02914067
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	N/A
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Washington University School of Medicine
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	Stephanie Perkins, M.D.
Principal Investigator Affiliation	Washington University School of Medicine
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	United States
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Childhood Brain Tumor
Study Website:	View Trial Website

Arms & Interventions

Arms

Experimental: Cohort 1

Prior to surgery, subjects will have a complete standard of care history and physical exam by the neurosurgeon and then undergo peri-diagnostic neurocognitive testing utilizing the NIH Toolbox Cognitive Battery computer testing software for iPad (will take 45 minutes). The peri-diagnostic period will be defined as the period from first presentation to 2 weeks post-diagnosis or two weeks post-op, whichever is later. Participants will also undergo a rsfcMRI during their standard of care MRI imaging which will add 15 minutes to their scan time

Experimental: Cohort 2

Patients with diagnosis of a posterior tumor will undergo neurocognitive testing utilizing the NIH Toolbox. Testing will be every 6 months for children currently receiving therapy and annually for those that have completed all therapy for a total of 3 sessions. During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of time. rsfcMRI will be obtained every 6 months for children currently receiving therapy and annually for those that have completed therapy for a total of 3 rsfcMRIs for each patient. Patients in Cohort 1 will also be eligible to continue with the longitudinal assessment as just described. These participants will then undergo repeat neurocognitive testing using the NIH toolbox 6-9 months for an additional 3 testing sessions. rsfcMRI will be obtained during their follow-up imaging at 6-9 month intervals for a total of 3 additional rsfcMRIs (4 total scans).

Experimental: Cohort 3

During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time. rsfcMRI will be obtained annually for total of 3 rsfcMRIs for each patient.

Experimental: Cohort 4 Arm A

Undergo the following MRI images: RSFC MRI, T2/T1 MRI, and DTI. Will complete cognitive testing using the NIH Toolbox Cognitive Battery All patients will complete the Attention Deficit/Hyperactivity Disorder (ADHD) Rating Scale - 5 questionnaire. All patients will complete a self-reported assessment of neurological quality of life (QOL). Adult patients (age ≥ 18 years) will complete the adult version of the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function measure. All pediatric patients will complete the pediatric version of the Neuro-QOL Cognitive Function measure. For patients <18 years of age and for adult patients with parent present, parent/caregiver will complete the PROMIS® Parent Proxy for cognition. All adult patients will complete the Colorado Learning Difficulties Questionnaire (CLDQ). This questionnaire will be completed by parent/caregiver for patients < 18 years of age.

Experimental: Cohort 4 Arm B

During standard of care MRI images, rsfcMRI imaging will be performed which will add 15 minutes of scan time. Will complete cognitive testing using the NIH Toolbox Cognitive Battery All patients will complete the Attention Deficit/Hyperactivity Disorder (ADHD) Rating Scale - 5 questionnaire. All patients will complete a self-reported assessment of neurological quality of life (QOL). Adult patients (age ≥ 18 years) will complete the adult version of the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function measure. All pediatric patients will complete the pediatric version of the Neuro-QOL Cognitive Function measure. For patients <18 years of age and for adult patients with parent present, parent/caregiver will complete the PROMIS® Parent Proxy for cognition. All adult patients will complete the Colorado Learning Difficulties Questionnaire (CLDQ). This questionnaire will be completed by parent/caregiver for patients < 18 years of age.

Interventions

Other: - Neurocognitive testing

Device: - rsfcMRI

The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Washington University School of Medicine, Saint Louis, Missouri

Status

Recruiting

Address

Washington University School of Medicine

Saint Louis, Missouri, 63110

Site Contact

Stephanie Perkins, M.D.

[email protected]

314-273-2931